BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed Price. Currency in USD
43.33
-0.72 (-1.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close44.05
Open44.11
Bid43.30 x 3000
Ask43.35 x 800
Day's Range43.26 - 44.19
52 Week Range43.26 - 63.69
Volume11,896,189
Avg. Volume13,210,146
Market Cap70.876B
Beta (3Y Monthly)0.73
PE Ratio (TTM)13.80
EPS (TTM)3.14
Earnings DateJul 25, 2019
Forward Dividend & Yield1.64 (3.72%)
Ex-Dividend Date2019-07-03
1y Target Est55.63
Trade prices are not sourced from all markets
  • 8 More Big Pharma Events in 2019 You Don't Want to Miss
    Motley Fool12 hours ago

    8 More Big Pharma Events in 2019 You Don't Want to Miss

    These are the clinical trial readouts, FDA decisions, and blockbuster-drug launches that will set the tone for the entire industry.

  • Is a Beat in the Cards for Bristol-Myers (BMY) Q2 Earnings?
    Zacks2 days ago

    Is a Beat in the Cards for Bristol-Myers (BMY) Q2 Earnings?

    Investors will focus on regular top- and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports second-quarter results.

  • Top Research Reports for Abbott, Netflix & Philip Morris
    Zacks2 days ago

    Top Research Reports for Abbott, Netflix & Philip Morris

    Top Research Reports for Abbott, Netflix & Philip Morris

  • Bristol-Myers, Ono, Bayer Team Up for Colorectal Cancer Study
    Zacks2 days ago

    Bristol-Myers, Ono, Bayer Team Up for Colorectal Cancer Study

    Bristol-Myers (BMY), Ono Pharmaceutical and Bayer ink a collaboration deal to evaluate the combination of Opdivo plus Stivarga for treating micro-satellite stable metastatic colorectal cancer.

  • These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
    Investor's Business Daily3 days ago

    These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger

    Gilead Sciences should acquire Celgene's psoriasis drug Otezla, but only for less than $9.6 billion, analysts said Thursday. Celgene is divesting Otezla ahead of its Bristol-Myers merger.

  • Reuters3 days ago

    Market-based pricing disappearing on blue-chip US loans

    Market-based pricing is disappearing in US investment grade lending as Credit Default Swaps (CDS) become a less relevant measurement of risk, and lenders feel less need to buy protection against the loans as top companies continue to perform in a stable economy. The practice was introduced after the 2008 financial crisis when several blue-chip companies drew down on revolving credit facilities, shocking banks that had charged minimal interest margins on the assumption that the loans would remain undrawn. Market-based pricing was endorsed by banks such as JP Morgan and Bank of America Merrill Lynch and was designed to make significantly low pricing on investment grade loans more dynamic.

  • Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks3 days ago

    Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth

    Bristol-Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • PR Newswire3 days ago

    Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer

    - Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer - Companies plan indication-seeking trial WHIPPANY, ...

  • Business Wire3 days ago

    Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Enter Into a Clinical Collaboration Agreement to Investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as Combination Therapy in Patients With Metastatic Colorectal Cancer

    WHIPPANY, N.J. & PRINCETON, N.J. & OSAKA, Japan-- -- Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer Companies plan indication-seeking trial   Bayer, Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. announced today the three companies have entered into a clinical collaboration agreement ...

  • Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?
    Zacks5 days ago

    Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?

    Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.

  • Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study
    Zacks5 days ago

    Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study

    Exelixis (EXEL) adds four cohorts and expands two cohorts in the early-stage study evaluating lead drug, Cabometyx, in combination with Tecentriq.

  • Markit5 days ago

    See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.

    Bristol-Myers Squibb Co NYSE:BMYView full report here! Summary * Perception of the company's creditworthiness is positive * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for BMY with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on July 12. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BMY had net inflows of $8.49 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. BMY credit default swap spreads are near the lowest level of the last one year and indicate improvement in the market's perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Why Bristol-Myers Squibb Company (NYSE:BMY) Is A Financially Healthy Company
    Simply Wall St.5 days ago

    Why Bristol-Myers Squibb Company (NYSE:BMY) Is A Financially Healthy Company

    With a market capitalization of US$72b, Bristol-Myers Squibb Company (NYSE:BMY) is a large-cap stock, which is...

  • Benzinga5 days ago

    Jim Cramer Weighs In On Marvell, General Motors And More

    Jim Cramer said Monday on “ Mad Money " that Marvell Technology Group Ltd. (NASDAQ: MRVL ) is a buy, calling it the No. 1 5G name. Cramer doesn't like any auto companies and would avoid General Motors ...

  • Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
    Zacks6 days ago

    Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

    Bristol-Myers Squibb (BMY) closed at $44.19 in the latest trading session, marking a -0.18% move from the prior day.

  • Will Bristol-Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
    Zacks6 days ago

    Will Bristol-Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

    Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Reuters6 days ago

    Biden healthcare plan would curb drug prices, raise taxes on rich

    Former U.S. Vice President Joe Biden, the front-runner in the Democratic presidential race, unveiled a healthcare plan on Monday estimated to cost $750 billion and paid for partly by higher tax rates for the wealthy and doubled tax rates on capital gains. "The Biden plan to protect and build on the Affordable Care Act" seeks to strengthen the signature healthcare plan, popularly known as Obamacare, enacted under former Democratic President Barack Obama. Biden was Obama's vice president for eight years.

  • Gilead to Boost Stake in Galapagos as Part of $5.1 Billion Deal
    Bloomberg6 days ago

    Gilead to Boost Stake in Galapagos as Part of $5.1 Billion Deal

    (Bloomberg) -- Gilead Sciences Inc. agreed to pay $5.1 billion to raise its stake in biotechnology company Galapagos NV to deepen its research into inflammatory diseases and other disorders, sending the Belgian drugmaker’s stock to an all-time high.The deal is the largest Gilead has executed since new Chief Executive Officer Dan O’Day took the reins in March as he attempts to bolster the San Francisco giant’s drug pipeline. Gilead is in danger of becoming a victim of its own success after launching some of the top drugs of all time, its bestselling hepatitis-C franchise. Sales from those therapies have since declined due to increased competition.Under the agreement, Gilead, which will pay $3.95 billion upfront to Mechelen, Belgium-based Galapagos and invest $1.1 billion to raise its stake to 22% from 12.3%, the companies said in a statement. The investment, at 140.59 euros a share, is 9.7% higher than the Belgian company’s closing price on Friday. Galapagos shares surged as much as 17% on Monday, reaching 149.55 euros a share.“Gilead will significantly expand its pipeline in a smart and financially savvy expanded partnership deal with Galapagos, essentially gaining options on everything in their pipeline without having to acquire the company full out,” Jefferies analysts including Michael J. Yee and Andrew Tsai wrote in a note.As Gilead seeks to fill the growing hole left from its hepatitis drugs, the Galapagos announcement may signal a shift in focus. The smaller biotech has no oncology programs and instead focuses on research into diseases that have to do with inflammation and fibrosis, which is a kind of internal scarring.Gilead has also had research programs in such diseases, including through its collaboration with Galapagos, though some had speculated it may stake its future on cancer. Gilead is already the biggest shareholder of the Belgium company before the increase in stake, according to data compiled by Bloomberg. Now it gets the option to license all of Galapogos’s future, late-stage drug candidates.Gilead CEOO’Day, who joined Gilead from cancer giant Roche AG, said he’s not done making good on his promise to expand the pipeline. He noted the deal almost doubles Gilead’s research capacity and establishes a strong research base in Europe where the company has historically not been as active.“In no way is this the only thing that we’re looking at or the only thing that we’re going to do,” O’Day said in an interview. “You can look at this like it’s the beginning.”Gilead and Galapagos held talks about an expanded partnership prior to O’Day joining the company. He was briefed on those discussions after taking the top job and within the first couple of weeks, got to know the CEO of Galapagos better. Following those talks, the pair decided to being finalizing the agreement.Jobs in EuropeThis is a “science-driven deal,” Onno van de Stolpe, founder and chief executive officer of Galapagos, said in an interview. Gilead will be taking on more of the commercial side for Galapagos, helping the smaller company to focus on research. “We can now do more of what we’re good at.”The money being invested beyond the equity stake will be used largely to double Galapagos’s R&D staff to 1,000 from 500 over an unspecified time, Van de Stolpe said. Those jobs will be added in Belgium, the Netherlands and France. “It’s massive funding -- we don’t have a detailed plan yet on how to spend it,” he said.The pact includes a provision in which Gilead’s stake could rise to 29.9%, if Galapagos shareholders approve two warrants. The companies were already partners on an experimental drug for rheumatoid arthritis. That drug, filgotinib, hit its main goal in a late-stage study in March, triggering the Belgian biotech company’s shares to surge by the most in six months.Galapagos shares have risen 59% since the start of the year, compared with the 5.9% gain in Gilead’s stock.O’Day had a reputation as a dealmaker while at Roche, likely one of the reasons he was selected for Gilead’s top job at a time when the company needs to look externally to drive growth. He said that in this case, the companies opted for a partnership-style deal rather than a full takeover because full mergers can often destroy innovation as research and executive teams disband. Roche’s deal philosophy is much the same with the Swiss giant opting to leave many its units independently managed, even if it owns them in full.Gilead spent about $12 billion to buy Kite Pharma in 2017 for its research into a cutting-edge therapies known as CAR-T. While the treatments can prove near-miraculous for some patients, CAR-Ts have yet to become large sales drivers, falling far below the revenues Gilead needs to replace declining sales from its hepatitis-C franchise.Gilead is not the only large company with fading blockbusters. In June, AbbVie agreed to buy Allergan in a $63 billion megadeal in a bid to replace its bestselling Humira, the bestselling drug in the world. Celgene Corp. faced similar questions as the patent of its bestselling cancer drug aged before Bristol-Myers Squibb agreed to buy it for $74 billion in January.To contact the reporters on this story: Eric Pfanner in London at epfanner1@bloomberg.net;Rebecca Spalding in Boston at rspalding@bloomberg.netTo contact the editors responsible for this story: James Ludden at jludden@bloomberg.net, ;Drew Armstrong at darmstrong17@bloomberg.net, Kevin Miller, Linus ChuaFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • GuruFocus.com6 days ago

    52-Week Company Lows

    Details the 52-week lows for the following companies: Bristol-Myers Squibb, Simon Property Group, Bank of New York Mellon, Carnival Corp., State Street, and Kroger. Continue reading...

  • 3 U.S. Stocks to Watch in July
    Motley Fool8 days ago

    3 U.S. Stocks to Watch in July

    A drugmaker, a chipmaker, and a truck manufacturer are worth watching this month.

  • Drug Pricing Woes Linger on Repealing Drug Rebate Proposal
    Zacks9 days ago

    Drug Pricing Woes Linger on Repealing Drug Rebate Proposal

    Investors' skepticism runs rife as Trump drops the drug rebate proposal, pushing drugmakers to take center stage with regard to the controversial drug pricing issue.

  • AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLC
    Zacks9 days ago

    AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLC

    The FDA assigns an orphan drug designation to AstraZeneca's (AZN) Imfinzi for the treatment of small cell lung cancer, the most aggressive type of the ailment.

  • Why one top exec at this $105 billion drugmaker is 'very disappointed' with Trump
    Yahoo Finance9 days ago

    Why one top exec at this $105 billion drugmaker is 'very disappointed' with Trump

    Ruud Dobber, AstraZeneca’s biopharmaceuticals president, weighs in on the Trump administration walking back one change it had been seeking in the drug space.

  • GuruFocus.com10 days ago

    Dow Jones Passes 27,000 for the 1st Time

    Bed Bath & Beyond slumps on quarterly results Continue reading...

  • Health Care stocks help lead Wall Street rally
    Yahoo Finance Video9 days ago

    Health Care stocks help lead Wall Street rally

    Yahoo Finance's Brian Sozzi, Alexis Christoforous, and Anjalee Khemlani break down what's driving the health care sector higher.